Metabolic Parameters Predictive of Type 2 Diabetes in Obese Patients

A study examined whether differences in metabolic parameters among obese patients could serve as predictors of who will develop type 2 diabetes. The RESISTIN trial included 969 obese patients with normal glucose tolerance. Patients were assessed for eight years for the following: body mass index, waist circumference, fasting plasma glucose, fasting plasma insulin, homeostasis model assessment index, blood pressure, lipid profile, lipoprotein(a), adiponectin (ADN), resistin, leptin, high sensitivity reactive protein (Hs-CRP), tumor necrosis factor-α (TNF-α), retinol binding protein-4, adipsin, vaspin, visfatin, omentin-1, and chemerin. At eight-year follow-up, 429 patients maintained euglycemia, 133 developed dysglycemia, and 90 developed diabetes. Patients with dysglycemia had lower ADN and higher resistin compared with baseline. Patients with diabetes had lower ADN and higher resistin compared with baseline, as well as compared with euglycemic and dysglycemic patients. Dysglycemic patients and those with diabetes both had higher Hs-CRP and TNF-α compared with baseline, but patients with diabetes had even higher values compared with euglycemic and dysglycemic patients. Patients with diabetes had higher visfatin and lower omentin-1 compared with baseline and euglycemic patients. Lower adiponectin and higher resistin levels were correlated with an increased type 2 diabetes risk.